文献速递外周动脉疾病

经皮深静脉动脉化的疗效与耐久性:一项系统综述

Efficacy and Durability of Percutaneous Deep Vein Arterialization: A Systematic Review.
PubMed 文献 · Ann Vasc Surg · 2024-04-03

本系统综述纳入10项研究共233例无选择临界肢体缺血患者,评估经皮深静脉动脉化的疗效与安全性。技术成功率97%(95%CI 96.2%-97.9%),大截肢率21.8%(95%CI 21.1%-22.4%),伤口愈合率69.5%,并发症率13.8%,再干预率37.4%,全因死亡率15.7%。作者认为该技术安全,但研究样本小、随访不足1年,缺乏1级证据推荐常规使用。

要点

  • 经皮深静脉动脉化技术成功率为97%(95%CI 96.2%-97.9%)。
  • 大截肢率为21.8%(95%CI 21.1%-22.4%),伤口愈合率为69.5%(95%CI 67.9%-71.0%)。
  • 研究样本小且随访不足1年,缺乏1级证据推荐常规使用。

核心结论

  • 经皮深静脉动脉化对无选择临界肢体缺血患者是安全的。
  • 现有研究样本小且随访期不足1年,目前缺乏1级证据推荐常规使用。

研究设计与样本

  • 系统综述按照PRISMA声明执行,检索PubMed、Web of Sciences、OvidSP和Embase。
  • 预设检索词为「percutaneous deep vein arterialization」或「percutaneous deep venous arterialization」。
  • 仅纳入患者数≥5的研究,排除涉及开放或杂交深静脉动脉化的研究。
  • 共纳入10项研究,合计233例患者。

主要发现

  • 患者主要为无选择临界肢体缺血患者,中位随访12个月(范围1-63个月)。
  • 技术成功率为97%(95%CI 96.2%-97.9%)。
  • 大截肢率为21.8%(95%CI 21.1%-22.4%)。
  • 伤口愈合率为69.5%(95%CI 67.9%-71.0%),并发症率为13.8%(95%CI 11.7%-15.9%)。
  • 再干预率为37.4%(95%CI 34.9%-39.9%),全因死亡率为15.7%(95%CI 14.1%-17.2%)。

临床怎么用

  • 作者认为经皮深静脉动脉化对无选择临界肢体缺血患者是安全的。
  • 作者指出目前缺乏1级证据推荐常规使用。

局限性

  • 研究样本小且随访期不足1年。
  • 目前缺乏1级证据推荐常规使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular deep vein arteriaization (DVA) is a novel technique aimed at salvaging peripheral arterial disease unamenable to conventional surgical intervention. This study aims to review contemporary literature on the efficacy, safety, and durability of DVA on patients with no-option critical limb ischemia (NO-CLI). METHODS: The study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, using predefined search terms of "percutaneous deep vein arterialization" or "percutaneous deep venous arterialization" in PubMed, Web of Sciences, OvidSP, and Embase. Only studies with 5 or more patients were included, and studies involving open or hybrid DVA were excluded. The primary outcomes included technical success and primary amputation rates. Secondary outcomes included rates of wound healing, complication, reintervention, and all-cause mortality. RESULTS: Ten studies encompassing a total of 233 patients were included. Patients were primarily those deemed to have NO-CLI. The median follow-up period was 12 months (range 1-63 months). The technical success rate was 97% (95% confidence interval [CI] 96.2%-97.9%) and the major amputation rate was 21.8% (95% 21.1%-22.4%). The wound healing rate was 69.5% (95% CI 67.9-71.0%), complication rate was 13.8% (95% CI 11.7%-15.9%), reintervention rate was 37.4% (95% CI 34.9%-39.9%), and all-cause mortality rate was 15.7% (95% CI 14.1%-17.2%). CONCLUSIONS: Our study showed that endovascular DVA is safe for patients with NO-CLI. Nonetheless, studies were small with follow-up period of less than 1 year. There is currently lack of level 1 evidence to recommend routine use in patients with NO-CLI.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. So SE, Chan YC, Cheng SW, et al. Efficacy and Durability of Percutaneous Deep Vein Arterialization: A Systematic Review. Ann Vasc Surg. 2024. PMID: 38579910. doi:10.1016/j.avsg.2024.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。